Robert D. Allen III has sold IVVD and made no open-market buys since Feb 2026

Robert D. Allen III, Ph.D., is the Chief Scientific Officer of Invivyd, Inc., a position he has held since April 11, 2023( With over 30 years of experience in virology and infectious disease, Allen brings extensive expertise in antiviral therapeutic development and clinical execution( He holds a Ph.D. in Microbiology from Columbia University, an M.S. in Applied Biology from Georgia Institute of Technology, and a B.S. in Biology from Rhodes College( Allen completed postdoctoral training in virology at Washington University in St. Louis and Emory University and has published extensively in the field(

Prior to joining Invivyd, Allen served as Chief Scientific Officer of SmartPharm Therapeutics (a Sorrento Therapeutics subsidiary) from 2020 to 2023, where he led the development of gene-encoded monoclonal antibodies for COVID-19 designed to be rapidly adapted to emerging variants( He also held the concurrent role of Senior Vice President of Antiviral and Oncolytic Immunotherapy Development at Sorrento Therapeutics( His earlier career included senior scientific positions at SIGA Technologies and the Oregon Translational Research and Development Institute( Under Allen's scientific leadership at Invivyd, the company achieved significant operational progress, with quarterly revenue increasing from $2.26 million in Q2 2024 to $13.13 million in Q3 2025(

Written by Perplexity from public sources.